The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Brandon Capital, a life sciences venture capital firm has exited from its investment in Myricx Bio, following its agreement to be acquired by Novartis for US$1.5 billion ($2.2bn).

The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...

Japanese biotech drug aims to reverse tooth loss by regrowing teeth. Here's how TRG-035 works, where trials stand and when it ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Preview this article 1 min A Madrid, Spain-based cancer diagnostic firm seeks to grow its footprint to 21,000-square-foot at ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.